MAPS revealed headline results from their successful Phase 3 trial of MDMA-assisted therapy for PTSD. The data reveal promising efficacy and safety profiles, which will be put to the test once more as MAPS undertakes a second Phase 3 study. The non-profit is on-track for a potential FDA approval in 2023. The search for new indications to target with psychedelic medicines – a trend we have been…


Previous articleCancer Patients’ Life Lessons Post-Psilocybin Treatment
Next articlePsychedelic Research Bulletin: April 2021